Doctors track lung cancer Drug's Real-Life impact in russia
NCT ID NCT05456867
Summary
This study observes how the drug durvalumab works for patients with stage III non-small cell lung cancer in everyday Russian clinics. It follows 250 patients who have already started the drug after completing chemo-radiation therapy. The main goal is to collect real-world information on the drug's safety, how long patients stay on treatment, and what happens after they stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC, NON-SMALL-CELL LUNG CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Arkhangelsk, Russia
-
Research Site
Chelyabinsk, Russia
-
Research Site
Grozny, Russia
-
Research Site
Irkutsk, Russia
-
Research Site
Khanty-Mansiysk, Russia
-
Research Site
Kostroma, Russia
-
Research Site
Krasnodar, Russia
-
Research Site
Krasnoyarsk, Russia
-
Research Site
Moscow, Russia
-
Research Site
Murmansk, Russia
-
Research Site
Nizhny Novgorod, Russia
-
Research Site
Novosibirsk, Russia
-
Research Site
Perm, Russia
-
Research Site
Saint Petersburg, Russia
-
Research Site
Sochi, Russia
-
Research Site
Surgut, Russia
-
Research Site
Tomsk, Russia
-
Research Site
Ufa, Russia
-
Research Site
Vologda, Russia
-
Research Site
Yaroslavl, Russia
-
Research Site
Yekaterinburg, Russia
-
Research Site
Yuzhno-Sakhalinsk, Russia
Conditions
Explore the condition pages connected to this study.